Zydus Lifesciences Ltd (ZYDUSLIFE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Zydus Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording of the Company's Investor Call
Audio / Video · 05 Nov 2026, 12:49 am
Zydus Lifesciences Releases Audio Recording of Q2 FY27 Earnings Call Zydus Lifesciences has made available the audio recording of its investor call on its official website. The call, held following the release of unaudited financial results for the quarter and half-year ended 30th Sep'26, was formally disclosed to the stock exchanges on 4th Nov'26 in compliance with SEBI Listing Regulations.
Press Release
Press Release · 04 Nov 2026, 6:10 pm
Zydus Lifesciences Reports Q2 FY27 Results with 29% Revenue Growth Zydus Lifesciences reported consolidated revenue of Rs. 79,096 mn for Q2 FY27, up 29.2% YoY, supported by India Formulations (+18.3% YoY to Rs. 18,844 mn) and North America Formulations (+20.8% YoY to Rs. 33,145 mn). EBITDA declined 6.0% YoY to Rs. 18,945 mn, with margins contracting to 24.0% from 32.9% in Q2 FY26. Net profit dropped 26.6% YoY to Rs. 9,255 mn. R&D investments stood at Rs. 6,573 mn (8.3% of revenues). Net debt to EBITDA reached 0.62x as of 30th Sep'26.
Investor presentation
Investor Presentation · 04 Nov 2026, 6:07 pm
Zydus Lifesciences Q2 FY27 Financial and Operational Performance Summary Zydus Lifesciences reported a 29.2% YoY increase in consolidated revenue from operations to Rs. 79,096 mn for Q2 FY27, driven by 20.8% YoY growth in North America formulations (Rs. 33,145 mn) and 18.3% YoY growth in India formulations (Rs. 18,844 mn). EBITDA declined 6.0% YoY to Rs. 18,945 mn with margins contracting 890 bps to 24.0%. Reported net profit fell 26.6% YoY to Rs. 9,255 mn, impacted by higher depreciation and operating expenses. Organic capex stood at Rs. 4,655 mn, while net debt closed at Rs. 51,998 mn.
Appointment of statutory auditors pursuant to mandatory auditor rotation
Change in Auditor · 04 Nov 2026, 6:02 pm
Zydus Lifesciences Appoints Walker Chandiok & Co as Statutory Auditors On 4th Nov'26, the Board of Directors of Zydus Lifesciences Limited approved the appointment of Walker Chandiok & Co LLP (a member firm of Grant Thornton International) as the company's statutory auditors, subject to shareholder approval. The appointment covers a five-year term from the conclusion of the 32nd AGM for FY27 until the 37th AGM for FY32. This follows mandatory auditor rotation under Section 139(2) of the Companies Act, 2013, as existing auditor Deloitte Haskins and Sells LLP completes its second consecutive five-year tenure.
Outcome of Board Meeting held on November 4, 2026
Outcome · 04 Nov 2026, 5:56 pm
Unaudited Financial Results for the quarter and half year ended on September 30, 2026
Financial Result · 04 Nov 2026, 5:54 pm
Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 5:49 pm
Zydus Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 79,096 (+29.2% YoY | -1.3% QoQ) ■ EBITDA: 18,945 (-6.0% YoY | -1.8% QoQ) ■ EBITDA Margin (%): 24.0 (-897 bps YoY | -11 bps QoQ) ■ PAT: 9,255 (-26.6% YoY | -3.6% QoQ) ■ EPS (INR): 9.28 (-25.9% YoY | -2.9% QoQ) Zydus Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Pharmaceuticals ■ Revenue: 65,582 (+23.2% YoY | +4.1% QoQ) ■ EBIT: 13,186 (-25.7% YoY | +5.9% QoQ) ■ EBIT Margin (%): 20.1 (-1325 bps YoY | +34 bps QoQ) Consumer products ■ Revenue: 11,257 (+73.5% YoY | -21.6% QoQ) ■ EBIT: 71.0 (Loss to Profit YoY | -95.6% QoQ) ■ EBIT Margin (%): 0.6 (Loss to Profit YoY | -1060 bps QoQ) Medical technologies ■ Revenue: 2,257 (+47.3% YoY | -20.2% QoQ) ■ EBIT: -928 (-169.0% YoY | -62.8% QoQ) ■ EBIT Margin (%): -41.1 (-1860 bps YoY | -2098 bps QoQ)
Update on acquisition of API business
Others (Uncategorized) · 02 Nov 2026, 6:16 pm
Zydus Lifesciences Completes Acquisition of Sterling Biotech API Business Zydus Lifesciences Limited has formally completed the acquisition of the active pharmaceutical ingredient (API) business of Sterling Biotech Limited. The transaction concluded following the fulfillment of all conditions precedent and closing date adjustments outlined in the Business Transfer Agreement originally executed between the parties on 17th Sep'24.
Changes in Senior Management team
Change in Management · 01 Nov 2026, 1:01 am
Zydus Lifesciences Appoints Christoph Stoller as Head of International Markets Zydus Lifesciences announced that Dr. Amrut Naik resigned as President and Business Unit Head, International Markets Business on 31st Oct'26, effective 7th Nov'26. The Board approved the appointment of Christoph Stoller as his successor effective 2nd Nov'26. Stoller brings over 30 years of global pharmaceutical experience, previously managing >USD 750 million P&L at Glenmark across EMEA, LATAM, and APAC, and holding senior leadership roles at Teva Pharmaceuticals with up to USD 2 billion P&L oversight.
Q2 FY27 post results earning call details
Intimation · 04 Nov 2026, 3:30 pm
Zydus Lifesciences Schedules Q2 FY27 Earnings Call on 4th Nov'26 Zydus Lifesciences Limited will announce its financial results for Q2 FY27 (July–September 2026) on 4th Nov'26. Managing Director Dr. Sharvil Patel will host a post-results earnings Q&A webinar on the same day at 3:30 p.m. IST. The company's earnings presentation, audio recording, and transcript will be accessible via its investor relations portal following the announcement.
Zylidac Bio and Prolific Machines Partner to Scale Prolific''s Next-Generation Biologics Manufacturing Platform to GMP Production.
Press Release · 21 Oct 2026, 11:57 pm
Zydus Group's Zylidac Bio Partners with Prolific Machines for Biologics Scale-Up Zylidac Bio, a CDMO within the Zydus Lifesciences group, partnered with Prolific Machines on 21st Oct'26 to scale Prolific's optogenetics-enabled biologics manufacturing platform to GMP production. Prolific's light-controlled protein expression technology achieved 21 g/L productivity in a 15-day fed-batch CHO run for monoclonal antibodies. Under the agreement, Zylidac will execute a technology transfer at a 50-liter scale at its Emeryville facility, with subsequent scaling planned to 250 liters and full commercial GMP production using existing bioreactors.
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity.
Press Release · 21 Oct 2026, 4:42 pm
Zydus Receives USFDA Approval for Estradiol and Levonorgestrel Transdermal System Zydus Lifesciences received final USFDA approval for its generic Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg/day), referenced to Climara Pro. Designated as a Competitive Generic Therapy (CGT), the product is eligible for 180 days of marketing exclusivity upon commercial launch. Indicated for menopause symptoms and osteoporosis prevention, it will be manufactured at Moraiya, Ahmedabad. The drug registered annual US sales of ~$45.7 mn (IQVIA MAT Aug'26). As of 30th Sep'26, Zydus holds 458 USFDA approvals and 516 filed ANDAs.
ZYDUS LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation · 04 Nov 2026, 5:30 am
Zydus Lifesciences Schedules Board Meeting on 4th Nov'26 for Q2/H1 Earnings Zydus Lifesciences Limited has scheduled its Board of Directors meeting for 4th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the company's trading window for directors and designated persons will remain closed until 6th Nov'26 and will reopen for trading on 9th Nov'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
ESG Rating
Others (Uncategorized) · 16 Oct 2026, 10:24 pm
Zydus Lifesciences Receives 'Leader' Category ESG Rating of 71 from NSRAL NSE Sustainability Ratings and Analytics Limited (NSRAL) has assigned an overall ESG rating of 71 to Zydus Lifesciences Limited for FY26, categorizing the pharmaceutical company as a 'Leader'. Received on 15th Oct'26, the unsolicited rating was prepared independently by the SEBI-registered ESG rating provider utilizing publicly available data.
Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.
Press Release · 15 Oct 2026, 5:01 pm
Zydus Lifesciences JV to Invest USD 20 Million in Sri Lanka Manufacturing Facility Zydus Sunshine Lifesciences (Pvt) Ltd, a JV between Zydus Lifesciences and Sunshine Healthcare (part of Sunshine Holdings PLC), signed an agreement on 13th Oct'26 with the Board of Investment of Sri Lanka. The JV will establish a pharmaceutical manufacturing facility across nearly four acres in Horana, Sri Lanka, with a phased investment exceeding USD 20 million. Phase one will produce oral solid dosage forms for the Sri Lankan market, with commercial operations scheduled to begin in 2028, subject to regulatory approvals.
USFDA Inspection
Press Release · 14 Oct 2026, 1:58 am
USFDA Concludes Inspection at Zydus Lifesciences' Moraiya Facility with Five Observations The USFDA concluded a regulatory inspection at Zydus Lifesciences Limited's manufacturing plant located in Moraiya, Ahmedabad, conducted from 5th Oct'26 to 13th Oct'26. The inspection closed with 5 observations. The company stated that it will work closely with the USFDA to address the noted observations expeditiously.
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.
Press Release · 13 Oct 2026, 3:20 pm
USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206 The USFDA accepted the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), marking the first publicly announced acceptance for a Keytruda biosimilar. Developed without comparative Phase III efficacy trials via an agreed USFDA pathway, the dossier is also submitted to Health Canada, with an FDA decision expected in Q3'27. Zydus holds exclusive commercialization rights in the US and Canada, triggering a milestone payment to partner Formycon. Keytruda generated worldwide sales of USD 31.7B in 2025 and USD 16.40B in 1H'26.
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across ....
Press Release · 12 Oct 2026, 11:30 pm
Zydus Presents Positive Phase 3 Saroglitazar Subgroup Data in PBC Zydus Lifesciences' subsidiary, Zydus Therapeutics, presented post hoc Phase 3 EPICS-III trial data for Saroglitazar in primary biliary cholangitis on 12th Oct'26. The drug demonstrated superior composite biochemical response versus placebo in both U.S. (60.7% vs. 0%; treatment difference Δ 60.7%) and non-U.S. subgroups (55.1% vs. 13.5%; Δ 41.6%). Saroglitazar was well tolerated and is currently under US FDA review, with Orphan Drug and Fast Track designations. Upon approval, Zydus plans to launch the drug in the U.S. by Mar'27.
Zydus, MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.
Press Release · 06 Oct 2026, 2:14 am
Zydus and MSN Launch First Generic of Adempas in the US Zydus Lifesciences partnered with MSN Laboratories to launch the first generic version of Adempas (Riociguat Tablets) in the US across all five strengths (0.5 mg to 2.5 mg) following USFDA approval. Developed and manufactured by MSN, the drug treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The first-to-market generic launch captures significant commercial potential, targeting a therapy where branded Adempas recorded global sales of ~EUR 745mn (~$850mn) in CY25, strengthening Zydus's specialty complex-generics US portfolio.
Extension of date of closing
Others (Uncategorized) · 02 Oct 2026, 3:05 am
Zydus Lifesciences Extends Timeline for 50:50 Joint Venture with Sunshine Healthcare Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited have mutually agreed to extend the closing timeline for their proposed 50:50 joint venture, Zydus Sunshine Lifesciences (Private) Limited. Following their initial agreement executed on 26th Jun'26 to acquire a 50% equity stake, both entities executed an extension letter on 1st Oct'26 as condition precedents remain ongoing. The transaction is now expected to reach final completion by Dec'26.
USFDA inspection concludes at Zydus'' manufacturing plant at SEZ II, Ahmedabad.
Press Release · 28 Sept 2026, 11:35 pm
USFDA Concludes Inspection at Zydus Lifesciences' Ahmedabad SEZ II Facility The USFDA conducted a current Good Manufacturing Practice (cGMP) inspection at Zydus Lifesciences' manufacturing facility located at SEZ II, Ahmedabad, from 21st Sep'26 to 28th Sep'26. The inspection concluded with a single observation, with no data integrity-related issues identified. The company stated it will work closely with the USFDA to expeditiously address the observation.
USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus'' USA Office with nil observations.
Press Release · 26 Sept 2026, 5:57 pm
USFDA Concludes Inspection at Zydus' USA Office with Nil Observations The USFDA conducted an on-site inspection of the pharmacovigilance and post-marketing surveillance systems at Zydus Lifesciences Limited's office located in New Jersey, USA. The regulatory audit took place from 22nd Sep'26 to 25th Sep'26 and concluded successfully with nil observations, reaffirming regulatory compliance for the company's US operations.
Credit Rating
Others (Uncategorized) · 11 Sept 2026, 8:05 pm
CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook CRISIL Ratings reaffirmed Zydus Lifesciences Limited's long-term rating at CRISIL AAA/Stable for Rs. 4,724 crore bank facilities and Rs. 125 crore NCDs, alongside CRISIL A1+ for short-term facilities and Rs. 200 crore commercial paper on 10th Sep'26. Ratings reflect the company’s dominant domestic formulations standing, expanding international presence, and robust financial profile. Despite adjusted debt rising to Rs. 12,515 crore in FY26 due to acquisitions, net debt to Ebitda remained strong at 0.60x, with Rs. 7,465 crore in cash and equivalents ensuring superior liquidity.